Crinetics Pharmaceuticals Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 210

Employees

  • Stock Symbol
  • CRNX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $47.47
  • (As of Friday Closing)

Crinetics Pharmaceuticals General Information

Description

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 10222 Barnes Canyon Road
  • Building 2
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Crinetics Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Crinetics Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$47.47 $48.63 $15.76 - $53.70 $3.74B 78.9M 896K -$3.78

Crinetics Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 3,141,055 1,874,236 619,692 1,159,469
Revenue 1,974 4,013 4,737 1,078
EBITDA (252,893) (226,867) (167,252) (106,876)
Net Income (235,464) (214,529) (163,918) (107,641)
Total Assets 978,153 635,353 352,176 351,015
Total Debt 52,504 51,728 3,075 3,074
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Crinetics Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Crinetics Pharmaceuticals‘s full profile, request access.

Request a free trial

Crinetics Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Crinetics Pharmaceuticals‘s full profile, request access.

Request a free trial

Crinetics Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and comm
Drug Discovery
San Diego, CA
210 As of 2022
00000
000000000 00000

000000

nim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea comm
0000000000000
Newark, CA
000 As of 0000
00000
00000000 00000

000000

veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Waltham, MA
000 As of 0000
00000
000000000 00 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Crinetics Pharmaceuticals Competitors (70)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Protagonist Therapeutics Formerly VC-backed Newark, CA 000 00000 00000000 00000
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA 000 00000 000000000 00 00000
Onconova Therapeutics Formerly VC-backed Newtown, PA 00 00000 00000000 00000
Nektar Therapeutics Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
ProMIS Neurosciences Corporation Toronto, Canada 0 000.00 000000000 000.00
You’re viewing 5 of 70 competitors. Get the full list »

Crinetics Pharmaceuticals Patents

Crinetics Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230159532-A1 Parathyroid hormone (pth) receptor antagonists and uses thereof Inactive 30-Sep-2021 0000000000
EP-4351654-A1 Non-peptide targeted therapeutics and uses thereof Pending 09-Jun-2021 000000000
US-20220387420-A1 Uses of a somatostatin modulator for the treatment of disease Pending 25-May-2021 00000000000 0
CA-3216457-A1 Uses of a somatostatin modulator for the treatment of disease Pending 25-May-2021 00000000000
AU-2022281327-A1 Uses of a somatostatin modulator for the treatment of disease Pending 25-May-2021 A61K31/4709
To view Crinetics Pharmaceuticals’s complete patent history, request access »

Crinetics Pharmaceuticals Executive Team (13)

Name Title Board Seat Contact Info
Richard Struthers Ph.D Co-Founder & Chief Executive Officer
Marc Wilson Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Jeff Knight Chief Operating Officer, Operations
Adriana Cabré Chief Human Resources Officer
Stephen Betz Ph.D Chief Scientific Officer & Founder
You’re viewing 5 of 13 executive team members. Get the full list »

Crinetics Pharmaceuticals Board Members (13)

Name Representing Role Since
Camille Bedrosian MD Self Board Member 000 0000
Caren Deardorf Self Board Member 000 0000
Matthew Fust Self Board Member 000 0000
Rogerio Vivaldi Coelho MD Self Board Member 000 0000
Rogerio Vivaldi Coelho Crinetics Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Crinetics Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Crinetics Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Crinetics Pharmaceuticals‘s full profile, request access.

Request a free trial

Crinetics Pharmaceuticals Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Radionetics Oncology 03-Jan-2024 00000 0000 000.00 Drug Discovery
To view Crinetics Pharmaceuticals’s complete investments history, request access »

Crinetics Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 16, 2023

31.92 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 456

Rank

00.00

Percentile

To view Crinetics Pharmaceuticals’s complete esg history, request access »

Crinetics Pharmaceuticals FAQs

  • When was Crinetics Pharmaceuticals founded?

    Crinetics Pharmaceuticals was founded in 2008.

  • Who is the founder of Crinetics Pharmaceuticals?

    Yun-Fei Zhu Ph.D, Stephen Betz Ph.D, Richard Struthers Ph.D, and Stephen Betz Ph.D are the founders of Crinetics Pharmaceuticals.

  • Who is the CEO of Crinetics Pharmaceuticals?

    Richard Struthers Ph.D is the CEO of Crinetics Pharmaceuticals.

  • Where is Crinetics Pharmaceuticals headquartered?

    Crinetics Pharmaceuticals is headquartered in San Diego, CA.

  • What is the size of Crinetics Pharmaceuticals?

    Crinetics Pharmaceuticals has 210 total employees.

  • What industry is Crinetics Pharmaceuticals in?

    Crinetics Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Crinetics Pharmaceuticals a private or public company?

    Crinetics Pharmaceuticals is a Public company.

  • What is Crinetics Pharmaceuticals’s stock symbol?

    The ticker symbol for Crinetics Pharmaceuticals is CRNX.

  • What is the current stock price of Crinetics Pharmaceuticals?

    As of 24-May-2024 the stock price of Crinetics Pharmaceuticals is $47.47.

  • What is the current market cap of Crinetics Pharmaceuticals?

    The current market capitalization of Crinetics Pharmaceuticals is $3.74B.

  • What is Crinetics Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Crinetics Pharmaceuticals is $1.97M.

  • Who are Crinetics Pharmaceuticals’s competitors?

    Protagonist Therapeutics, Apellis Pharmaceuticals, Onconova Therapeutics, Nektar Therapeutics, and ProMIS Neurosciences are some of the 70 competitors of Crinetics Pharmaceuticals.

  • What is Crinetics Pharmaceuticals’s annual earnings per share (EPS)?

    Crinetics Pharmaceuticals’s EPS for 12 months was -$3.78.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »